Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neovasc Inc. NVCN

Healthcare Medical Instruments & Supplies
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter... see more

Recent & Breaking News (NDAQ:NVCN)

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Newsfile May 25, 2021

Neovasc Provides Update on German Litigation

GlobeNewswire May 20, 2021

Neovasc to Sponsor Symposium on Reducer at EuroPCR

GlobeNewswire May 13, 2021

Neovasc Announces First Patient Enrollment in COSIMA Trial

GlobeNewswire May 10, 2021

Neovasc Announces First Quarter 2021 Financial Results

GlobeNewswire May 6, 2021

Neovasc Provides Reducer Reimbursement Progress Update

Newsfile April 28, 2021

Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021

Newsfile April 27, 2021

Neovasc Comments on EuroIntervention Article

GlobeNewswire April 19, 2021

Neovasc (TSX:NVCN) discloses setback with Tiara TA device

Trevor Abes  April 16, 2021

Neovasc Provides Tiara TA Update

GlobeNewswire April 16, 2021

Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results

Newsfile March 11, 2021

Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021

GlobeNewswire March 4, 2021

Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 3, 2021

Neovasc Comments on Clinical Cardiology Journal Publication

GlobeNewswire March 2, 2021

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

Newsfile February 24, 2021

Neovasc to Participate in 10th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 17, 2021

Neovasc Announces Closing of US$72 Million Registered Direct Offering of Common Shares Priced At-The-Market

GlobeNewswire February 12, 2021

Neovasc Announces US$72 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire February 10, 2021

Neovasc (TSX:NVCN) regains compliance with Nasdaq minimum bid price requirement

Isabella Zavarise February 9, 2021

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

Newsfile February 9, 2021